Cargando…
Re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model
BACKGROUND: Inadequate medicines optimisation and adherence are significant problems among patients taking secondary prevention medications following myocardial infarction (MI). A novel joint consultant cardiology pharmacist and cardiologist medicines optimisation clinic was initiated for patients r...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307610/ https://www.ncbi.nlm.nih.gov/pubmed/30613417 http://dx.doi.org/10.1136/openhrt-2018-000921 |
_version_ | 1783383034852016128 |
---|---|
author | Khatib, Rani Patel, Nasrin Laverty, Una Mcgawley, Gina McLenachan, Jim Shield, Sarah Hall, Alistair S |
author_facet | Khatib, Rani Patel, Nasrin Laverty, Una Mcgawley, Gina McLenachan, Jim Shield, Sarah Hall, Alistair S |
author_sort | Khatib, Rani |
collection | PubMed |
description | BACKGROUND: Inadequate medicines optimisation and adherence are significant problems among patients taking secondary prevention medications following myocardial infarction (MI). A novel joint consultant cardiology pharmacist and cardiologist medicines optimisation clinic was initiated for patients recently discharged following MI. METHODS: Patients completed a locally developed tool, the ‘My Experience of Taking Medicines’ questionnaire, designed to allow sharing of barriers to adherence with medications. They then attended a clinic with the consultant pharmacist or cardiologist (or both). Secondary prevention medicines needs and barriers to adherence were identified and discussed, and an action plan developed. The data provided are from a retrospective review of 270 post-MI patients attending the service between October 2015 and December 2016. RESULTS: Mean age was 67.3 years and 67.8% were male. The mean time from discharge to first outpatient clinic attendance was reduced by 56.1% (49.4 days vs 88 days before the service began). More than 95% of patient without planned non-pharmacological intervention postdischarge did not need a cardiologist’s input. Levels of medicines optimisation were improved substantially after attendance: patients receiving a recommended angiotensin-converting enzyme inhibitor/angiotensin receptor blocker dose increased from 16.3% to 73.9% (p<0.001); patients receiving a recommended beta-blocker dose increased from 6.2% to 46.1% (p<0.001). Patient concerns about their medications were significantly decreased (all p<0.001). Rates of non-adherence fell by 42.6%–70.8% at 3–6 months post-clinic. Readmission rates also declined after the service opened. CONCLUSIONS: A medicines optimisation and patient adherence strategy based on a joint consultant cardiology pharmacist and cardiologist clinic can improve both adherence and outcomes post-MI. |
format | Online Article Text |
id | pubmed-6307610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-63076102019-01-04 Re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model Khatib, Rani Patel, Nasrin Laverty, Una Mcgawley, Gina McLenachan, Jim Shield, Sarah Hall, Alistair S Open Heart Coronary Artery Disease BACKGROUND: Inadequate medicines optimisation and adherence are significant problems among patients taking secondary prevention medications following myocardial infarction (MI). A novel joint consultant cardiology pharmacist and cardiologist medicines optimisation clinic was initiated for patients recently discharged following MI. METHODS: Patients completed a locally developed tool, the ‘My Experience of Taking Medicines’ questionnaire, designed to allow sharing of barriers to adherence with medications. They then attended a clinic with the consultant pharmacist or cardiologist (or both). Secondary prevention medicines needs and barriers to adherence were identified and discussed, and an action plan developed. The data provided are from a retrospective review of 270 post-MI patients attending the service between October 2015 and December 2016. RESULTS: Mean age was 67.3 years and 67.8% were male. The mean time from discharge to first outpatient clinic attendance was reduced by 56.1% (49.4 days vs 88 days before the service began). More than 95% of patient without planned non-pharmacological intervention postdischarge did not need a cardiologist’s input. Levels of medicines optimisation were improved substantially after attendance: patients receiving a recommended angiotensin-converting enzyme inhibitor/angiotensin receptor blocker dose increased from 16.3% to 73.9% (p<0.001); patients receiving a recommended beta-blocker dose increased from 6.2% to 46.1% (p<0.001). Patient concerns about their medications were significantly decreased (all p<0.001). Rates of non-adherence fell by 42.6%–70.8% at 3–6 months post-clinic. Readmission rates also declined after the service opened. CONCLUSIONS: A medicines optimisation and patient adherence strategy based on a joint consultant cardiology pharmacist and cardiologist clinic can improve both adherence and outcomes post-MI. BMJ Publishing Group 2018-12-10 /pmc/articles/PMC6307610/ /pubmed/30613417 http://dx.doi.org/10.1136/openhrt-2018-000921 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Coronary Artery Disease Khatib, Rani Patel, Nasrin Laverty, Una Mcgawley, Gina McLenachan, Jim Shield, Sarah Hall, Alistair S Re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model |
title | Re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model |
title_full | Re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model |
title_fullStr | Re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model |
title_full_unstemmed | Re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model |
title_short | Re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model |
title_sort | re-engineering the post-myocardial infarction medicines optimisation pathway: a retrospective analysis of a joint consultant pharmacist and cardiologist clinic model |
topic | Coronary Artery Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307610/ https://www.ncbi.nlm.nih.gov/pubmed/30613417 http://dx.doi.org/10.1136/openhrt-2018-000921 |
work_keys_str_mv | AT khatibrani reengineeringthepostmyocardialinfarctionmedicinesoptimisationpathwayaretrospectiveanalysisofajointconsultantpharmacistandcardiologistclinicmodel AT patelnasrin reengineeringthepostmyocardialinfarctionmedicinesoptimisationpathwayaretrospectiveanalysisofajointconsultantpharmacistandcardiologistclinicmodel AT lavertyuna reengineeringthepostmyocardialinfarctionmedicinesoptimisationpathwayaretrospectiveanalysisofajointconsultantpharmacistandcardiologistclinicmodel AT mcgawleygina reengineeringthepostmyocardialinfarctionmedicinesoptimisationpathwayaretrospectiveanalysisofajointconsultantpharmacistandcardiologistclinicmodel AT mclenachanjim reengineeringthepostmyocardialinfarctionmedicinesoptimisationpathwayaretrospectiveanalysisofajointconsultantpharmacistandcardiologistclinicmodel AT shieldsarah reengineeringthepostmyocardialinfarctionmedicinesoptimisationpathwayaretrospectiveanalysisofajointconsultantpharmacistandcardiologistclinicmodel AT hallalistairs reengineeringthepostmyocardialinfarctionmedicinesoptimisationpathwayaretrospectiveanalysisofajointconsultantpharmacistandcardiologistclinicmodel |